Explorar vídeo

3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC

Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.

Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.

Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.

Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.

Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.